In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavirus-19 or COVID-19. The mortality of the virus has been reported around 2-10% and its causes because of the proinflammatory immune response generated on the host. The cytokines involved in the immune response to COVID-19 are IL-1, IL-2, IL4, IL-6, IL-10, IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1α, HGF, IFN-γ y TNF-α. Ruxolitinib is an inhibitor of JAK 1/2 which is responsable for multiple cellular signals including the proinflammatory IL-6. Ruxolitinib works as and immunomodulator decreasing the cytotoxic T lymphocytes and increasing the Treg cells. This study is intended to stop the disregulated immune response caused by COVID-19 that generates the pneumonia and subsequent severe acute respiratory syndrome.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
77
Ruxolitinib 5 mg twice a day
Grupo Cooperativo de Hemopatías Malignas
Huixquilucan, State of Mexico, Mexico
Recovery of Pneumonia
Presence of recovery of pneumonia characterized by cease of respiratory symptoms
Time frame: 14 days
Response of C-reactive protein
Increment or decrease in mg/ml of C-reactive protein
Time frame: 14 days
Response of Ferritin
Increment or decrease in ng/ml of ferritin
Time frame: 14 days
Response of D-dimer
Increment or decrease in mg/ml of D-dimer
Time frame: 14 days
Rate of ICU admission
Requirement of Intensive Care Unit on the patients under treatment
Time frame: 14 days
Rate of mechanical ventilation
Requirement of mechanical ventilation on the patients under treatment
Time frame: 14 days
Overall Survival
Time since the diagnosis to the last follow up (recovery or death)
Time frame: 1 month
Toxicity Rate
Rate of adverse events associated with ruxolitinib
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.